Ronen Ben-Ami

Dr. Ronen Ben-Ami

Infectious Diseases Unit, Molecular Mycology Laboratory, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2019 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
OCOliver A. Cornely
Oliver A. Cornely
AAAna Alastruey-Izquierdo
Ana Alastruey-Izquierdo
DADorothee Arenz
Dorothee Arenz
SCSharon C A Chen
Sharon C A Chen
Eric DannaouiEric Dannaoui
Eric Dannaoui
ACArunaloke Chakrabarti
Arunaloke Chakrabarti

28 April 2020 in mBio
Verified
Journal Article
Closed access
PDF file
NCNancy A. Chow
Nancy A. Chow
JMJose Munoz
Jose Munoz
LGLalitha Gade
Lalitha Gade
EBElizabeth L. Berkow
Elizabeth L. Berkow
XLXiao Li
Xiao Li
Christina CuomoChristina Cuomo
Christina Cuomo
In less than a decade, C. auris has emerged in health care settings worldwide; this species is capable of colonizing skin and causing outbreaks of invasive candidiasis. In contrast to other Candida species, C. auris is unique in its ability to spread via nosocomial transmission and its high rates of drug resistance. As part of the public health response, whole-genome sequencing has played a major role in characterizing transmission dynamics and detecting new C. auris introductions. Through a global collaboration, we assessed genome evolution of isolates of C. auris from 19 countries. Here, we described estimated timing of the expansion of each C. auris clade and of fluconazole resistance, characterized discrete phylogeographic population structure of each clade, and compared genome data to sensitivity measurements to describe how antifungal resistance mechanisms vary across the population. These efforts are critical for a sustained, robust public health response that effectively utilizes molecular epidemiology.

1 September 2009 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
RBRonen Ben-Ami
Ronen Ben-Ami
JBJesus Rodríguez Baño
Jesus Rodríguez Baño
HAHande Arslan
Hande Arslan
JPJohann D. D. Pitout
Johann D. D. Pitout
CQClaudine Quentin
Claudine Quentin
YCYehuda Carmeli
Yehuda Carmeli
Background. Infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae are increasing in frequency and are associated wit

1 April 2006 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
MSMitchell J. Schwaber
Mitchell J. Schwaber
SNShiri Navon-Venezia
Shiri Navon-Venezia
KKKeith S. Kaye
Keith S. Kaye
RBRonen Ben-Ami
Ronen Ben-Ami
DSDavid Schwartz
David Schwartz
YCYehuda Carmeli
Yehuda Carmeli
We studied outcomes of extended-spectrum β-lactamase (ESBL) production in Enterobacteriaceae bacteremia. Inpatients with bacteremia caused by ESBL-producing Escherichia coli , Klebsiella spp., or Proteus spp. (cases) were compared with patients with bacteremia caused by non-ESBL producers (controls). Outcomes included mortality, mortality due to infection, length of stay (LOS), delay in appropriate therapy (DAT), discharge to a chronic care facility, and hospital cost. Ninety-nine cases and 99 controls were enrolled. Thirty-five percent of cases died, versus 18% of controls (odds ratio [OR], 2.5; 95% confidence interval [CI], 1.3 to 4.7; P = 0.01). Thirty percent of cases died due to infection, versus 16% of controls (OR, 2.3; 95% CI, 1.1 to 4.5; P = 0.03). The median LOS after bacteremia for cases was 11 days (interquartile range, 5 to 21), versus 5 days for controls (interquartile range, 3 to 9) ( P < 0.001). DAT occurred in 66% of cases, versus 7% of controls (OR, 25.1; 95% CI, 10.5 to 60.2; P < 0.001). Cases were more likely than controls to be discharged to chronic care (52% versus 21%; OR, 4.0; 95% CI, 1.9 to 8.3; P < 0.001). The average hospital cost for cases was 65,509 Israeli shekels, versus 23,538 shekels for controls ( P < 0.001). After adjusting for differences between groups by using multivariable analysis, ESBL production remained a significant predictor of mortality (OR, 3.6; 95% CI, 1.4 to 9.5; P = 0.008), increased LOS (1.56-fold; P = 0.001), DAT (OR, 25.1; 95% CI, 10.5 to 60.2; P < 0.001), and increased cost (1.57-fold; P = 0.003). The mean increase in equivalent cost attributable to ESBL production was $9,620. ESBL production was associated with severe adverse outcomes, including higher overall and infection-related mortality, increased LOS, DAT, discharge to chronic care, and higher costs.

1 February 2021 in The Lancet
Verified
Journal Article
Closed access
MJMaertens Johan
Maertens Johan
GRGalia Rahav
Galia Rahav
DLDong-Gun Lee
Dong-Gun Lee
APAlfredo Ponce-De-León
Alfredo Ponce-De-León
ISIsabel Cristina Ramírez Sánchez
Isabel Cristina Ramírez Sánchez
HWHetty Waskin
Hetty Waskin

1 February 2017 in Emerging Infectious Diseases
Verified
Journal Article
Open access
RBRonen Ben-Ami
Ronen Ben-Ami
JBJudith Berman
Judith Berman
ANAna Novikov
Ana Novikov
EBEdna Bash
Edna Bash
YSYael Shachor-Meyouhas
Yael Shachor-Meyouhas
TFTalya Finn
Talya Finn
Candida auris and C. haemulonii are closely related, multidrug-resistant emerging fungal pathogens that are not readily distinguishable with phenotypic assays. We studied C. auris and C. haemulonii clinical isolates from 2 hospitals in central Israel. C. auris was isolated in 5 patients with nosocomial bloodstream infection, and C. haemulonii was found as a colonizer of leg wounds at a peripheral vascular disease clinic. Liberal use of topical miconazole and close contact among patients were implicated in C. haemulonii transmission. C. auris exhibited higher thermotolerance, virulence in a mouse infection model, and ATP-dependent drug efflux activity than C. haemulonii. Comparison of ribosomal DNA sequences found that C. auris strains from Israel were phylogenetically distinct from isolates from East Asia, South Africa and Kuwait, whereas C. haemulonii strains from different countries were closely interrelated. Our findings highlight the pathogenicity of C. auris and underscore the need to limit its spread.